GlobeNewswire Clinical StudiesOriginal article
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
RegulatorypositiveurcosimodPositive
AI Analysis
Summary
OKYO Pharma received positive feedback from an FDA Type D meeting for urcosimod in neuropathic corneal pain and announced acceleration into a global Phase 3 pivotal trial. The FDA meeting validated the company's regulatory and clinical development strategy.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Positive FDA Type D meeting feedback validating regulatory and clinical path forward for urcosimod
Importance:7/10
Sentiment:
0.80
FDA meetingregulatory approvalPhase 3 trialneuropathic corneal painophthalmology
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 8, 2026 11:00 AM